Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
5.75
-0.29 (-4.80%)
At close: Nov 21, 2024, 4:00 PM
5.77
+0.02 (0.34%)
After-hours: Nov 21, 2024, 4:17 PM EST

Recursion Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Revenue
65.1844.5839.8410.183.962.32
Revenue Growth (YoY)
37.64%11.88%291.46%156.89%70.85%-
Cost of Revenue
327.89283.81203.97135.2763.3245.81
Gross Profit
-262.71-239.24-164.13-125.09-59.36-43.49
Selling, General & Admin
132.54110.8281.657.6825.2618.95
Operating Expenses
132.54110.8281.657.6825.2618.95
Operating Income
-395.25-350.06-245.73-182.78-84.62-62.44
Interest Expense
-0.99-0.1-0.06-2.95-1.36-0.64
Interest & Investment Income
15.6619.126.250.070.341.74
Other Non Operating Income (Expenses)
-3.45-1.090.050-0.480.01
EBT Excluding Unusual Items
-384.03-332.13-239.48-185.65-86.12-61.32
Other Unusual Items
----0.83-0.88-0.56
Pretax Income
-382.95-332.13-239.48-186.48-87.01-61.88
Income Tax Expense
-5.2-4.06----
Net Income
-377.75-328.07-239.48-186.48-87.01-61.88
Net Income to Common
-377.75-328.07-239.48-186.48-87.01-61.88
Shares Outstanding (Basic)
2462081761252222
Shares Outstanding (Diluted)
2462081761252222
Shares Change (YoY)
23.57%18.41%40.04%475.48%0.98%-
EPS (Basic)
-1.54-1.58-1.36-1.49-3.99-2.87
EPS (Diluted)
-1.54-1.58-1.36-1.49-3.99-2.87
Free Cash Flow
-332.29-299.74-120.58-198.41-51.23-60.95
Free Cash Flow Per Share
-1.35-1.44-0.69-1.58-2.35-2.83
Operating Margin
-606.35%-785.33%-616.74%-1795.79%-2135.66%-2692.58%
Profit Margin
-579.51%-735.99%-601.05%-1832.18%-2196.01%-2668.35%
Free Cash Flow Margin
-509.76%-672.43%-302.65%-1949.42%-1293.03%-2628.37%
EBITDA
-364.15-325.66-233.97-174.37-80.67-59.95
D&A For EBITDA
31.124.411.768.413.942.49
EBIT
-395.25-350.06-245.73-182.78-84.62-62.44
Revenue as Reported
65.1844.5839.8410.183.962.32
Source: S&P Capital IQ. Standard template. Financial Sources.